Clinical trial NCT00618917: MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
Official title: Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Esophageal
Toxicity
Keywords: NSCLC
lung cancer
chemotherapy
radiation therapy
radiation toxicity
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2008-02-20
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis during concurrent paclitaxel and carboplatin chemotherapy with thoracic radiation in subjects with locally advanced non-small cell lung cancer (NSCLC).

Detailed description: This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis during concurrent paclitaxel and carboplatin chemotherapy with thoracic radiation in subjects with locally advanced non-small cell lung cancer (NSCLC). Phase I of the study will assess the feasibility and safety of MnSOD PL by dose escalation in 3 cohorts of 3 chemoradiotherapy subjects each (Cohort1 = 0.3 mg/dose, Cohort2 = 3 mg/dose, Cohort3 = 30 mg/dose). The highest dose completed (as determined by toxicity monitoring for 8 weeks from initial treatment) will be the starting dose for Phase II. Phase II will examine the efficacy of MnSOD PL by assessing the incidence of Grade 3 or 4 esophagitis in 27 additional chemoradiotherapy subjects. Incidence of esophageal toxicity, as well as clinical response to the combination of chemoradiotherapy with MnSOD PL are the outcomes of interest.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically documented NSCLC including squamous cell carcinoma, adenocarcinoma (including bronchoalveolar cell), and large cell anaplastic carcinoma (including giant and clear cell carcinomas) and poorly differentiated non-small cell lung cancer. Totally resected tumors are excluded.
* Subjects must be without evidence of M0.
* Subjects with T1 or T2 disease with N2 or tumor stage 3, lymph node metastasis 1-2 ( stage 1) disease (Stage IIIA) are eligible if they are medically inoperable. Subjects with T4 with any N or any T with N3 disease are eligible. Radiographic evidence of mediastinal lymph nodes \>2.0 cm in the largest diameter is sufficient to stage N2 or N3 disease. If the largest mediastinal node is \< 2.0 cm in diameter and this is the basis for stage III disease, then at least one of the nodes must be proven positive cytologically or histologically.
* Subjects with tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. The boost volume must be limited to \< 50% of the ipsilateral lung volume.
* Subjects with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy. Exudative, bloody, or cytologically malignant effusions are ineligible. If a pleural effusion can be seen on the chest CT but not on chest X-ray and is too small to tap, the subject will be eligible.
* Subjects must be deemed a suitable candidate for protocol treatment by both Radiation Oncology and Medical Oncology
* Subjects must have a Performance Status \> 70 (Karnofsky Performance Scale).
* Subjects Weight loss \< 10% in 3 months prior to diagnosis.
* Subjects must be male or female \> 18 years.
* Subjects must have had no prior systemic chemotherapy, radiation therapy to the thorax, or total surgical resection.
* At least 3 weeks since formal exploratory thoracotomy and the subject has recovered from surgery, or 1 week from diagnostic thoracoscopy.
* Laboratory values must be as follows: (See Section 6.1 of the full protocol for required timing): Granulocytes \> 2,000/ml, Platelets \> 100,000/ml, Hemoglobin\* \> 8 mg/dl, Bilirubin \< 1.5 x normal, Creatinine clearance \> 50 ml/n (24 hour or calculated, forced expiratory volume at one second \> 800 cc. Note: \*Physician can maintain a subject's hemoglobin with the use of Erythropoetin or transfusions prophylactic use of G-CSF (colony stimulating factor, is not permitted).
* Subjects must have a MRI or CT brain scan within 4 weeks prior to study entry to rule out asymptomatic brain metastases.
* Subjects must be informed of the investigational nature of the study and sign an informed consent form and have no serious medical or psychiatric illnesses that would prevent informed consent.
* No history of serious cardiac disease that is not adequately controlled.
* Female subjects must be non-pregnant and non-lactating. Female subjects of childbearing potential must implement an effective method of contraception during the study. All women of childbearing potential must have a pre-study negative serum or urine pregnancy test within 7 days prior to study entry.

Exclusion Criteria

* Inability to meet any of the above eligibility requirements

Primary outcomes:
measure: Determination of Recommended Phase II Dose of MnSOD/Plasmid DNA
timeFrame: Every 8 weeks, up to 2 years
measure: Radiation-induced Esophageal Toxicity
timeFrame: Up to 2 years
Secondary outcomes:
measure: Overall (Objective) Response
timeFrame: Up to 2 years
measure: Overall Survival (OS)
timeFrame: Up to 5 years
measure: Time to Disease Progression
timeFrame: Up to 5 years
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
affiliation: UPMC Hillman Cancer Center
name: Joel Greenberger, MD
role: PRINCIPAL_INVESTIGATOR
References: